https://raceoncology.com/category/media-release/page/8/?section=3&sl-year=2018
From 2018 - Race Oncology is pleased to announce the appointment of US-based Dr John Cullity as a non-executive director for Race Oncology. Dr Cullity has previously held senior executive roles with Sanofi-Aventis and ...
https://*********.com.au/race-oncology-agreement-pursue-bisantrene-cancer-drug-licensing/
Looks like the Sanofi connection is probably null and void (but it resulted in JC's 8m (cheap) shares).
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.[2]
So JC must have worked with Sanofi-Aventus between 2004 and 2011, using that association in his CV for the 2018 RAC appointment.
Sounds familiar ?, page-2
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
-0.055(3.64%) |
Mkt cap ! $243.3M | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.50 | $1.46 | $86.50K | 59.03K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 159 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.48 | 5964 | 1 |
View Market Depth
| Last trade - 16.10pm 23/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.46 |
Change
-0.055 ( 3.04 %) |
||||
| Open | High | Low | Volume | ||
| $1.46 | $1.50 | $1.46 | 17834 | ||
| Last updated 15.58pm 23/05/2024 ? | |||||
| RAC (ASX) Chart |